Transcript for 142 pharmaceutical companies sunbathe 2020! Kyusju Tong... Net profit exceeded $3 billion

Pharmaceutical Network January 29 according to statistics, as of January 27 close, A-share pharmaceutical companies have 142 disclosed the 2020 performance, more than 60% of the expected.
Huahua Pharmaceuticals became the first company in Shanghai and Shenzhen to disclose its annual report; Yingke Medical, Meirui Medical, Xin and Cheng, Kyushua Tong, Changchun Gaoxin net profit exceeded 3 billion yuan; and 1 billion to 3 billion yuan of pharmaceutical Mingkangde, Lizhu Group,, Toling Pharmaceuticals, Kanglong into 12, Yuheng Pharmaceuticals, Asia Pacific Pharmaceuticals, Ruikang Pharmaceuticals and other 10 are expected to turn a profit, from the growth rate, 41 doubled, Sanxiang Biology, Anke Medical, Da'an gene are more than 20 times.
addition, a total of 22 losses, of which, Concino, Junshi Bio, Baiotai and other 5 continued losses, double into the pharmaceutical industry, Jincheng Pharmaceuticals and other 9 first losses.
A-share pharmaceutical enterprises in 2020 performance situation A-share pharmaceutical enterprises 2020 results report A-share pharmaceutical enterprises 2020 results forecast a year surge of nearly 40 times! The net profit rose from less than 200 million to more than 7 billion British Medical recently released a results forecast, 2020 net profit of 6.8 billion to 7.3 billion yuan, up 3713.45 percent to 3993.85 percent, in 2019 its net profit of less than 200 million yuan.
For the performance of the big increase, Anglo Medical pointed out that, on the one hand, 2020 affected by the new crown outbreak, the global demand for disposable protective gloves surge, the company's disposable protective gloves products have a relatively large increase in the price of sales revenue and gross margins have increased significantly.
On the other hand, the company's Anhui production base has PVC glove production line and butyl glove production line put into operation, so that the reporting period glove production capacity increased significantly year-on-year, while the company through continuous internal excellence, improvement and innovation, further energy conservation and consumption reduction, improve production efficiency, improve product quality, gross margin has played a positive role in the improvement.
In addition, the Office of the United States Trade Representative exempts import duties on a wide range of medical products imported from China, including the company's main product, butyl gloves, which are exempt from the relevant tariffs to further increase the export competitiveness of the company's products and enhance the company's overall profitability.
and the company's growth in the protective goods trade sector, such as masks, isolation clothing, also played a role in promoting performance growth.
pharmaceutical circulation leading net profit broke 3 billion, the vitamin giant again high Kyusju Tong forecast 2020 net profit of 3,056 million to 3,201 million yuan, up 77% to 85% YoY.
Kyusju Tong said that the company's general agent distribution business, medical devices and other business rapid growth, while the company's gross margin continued to rise, the company's financing costs fell, tax cuts and fee reduction policy results gradually appear, the company's various management measures are also being strengthened.
It is worth mentioning that, in terms of non-operating profit and loss, the company's participation in the company's shares in the Shenzhen Stock Exchange GEM listing to form a fair value change profit and loss, as well as the wholly-owned subsidiary Shanghai Kyushak Tong Pharmaceutical Co., Ltd. to obtain land disposal compensation income, resulting in non-recurring profit and loss amount of about 1.218 billion yuan, the above factors jointly promote the company's 2020 net profit growth.
data show that this year, Kyusju pass action frequently.
On January 8, Kyushua Tong signed a Strategic Cooperation Agreement with Koxing Holdings (Hong Kong) Co., Ltd. to carry out business cooperation in vaccine commissioning distribution and refrigerated vehicle leasing, and on January 21, Kyushua Tong signed a long-term loan agreement with the Asian Development Bank and German Investment and Development Co., Ltd., and ADB and Germany issued a joint offer to Kyushua. 60 million euros of private sector loans for the expansion of Kyusju Tong's pharmaceutical logistics center, and on January 22, Kyusju tong and 360 formally reached a strategic cooperation, the two sides will be medical information and network security cooperation, intelligent logistics cooperation, Internet business and medical science and technology cooperation and other areas to deepen cooperation, integration of the advantages of resources, and jointly work to promote the healthy development of medical information, digital.
forecast 2020 net profit of 3.464 billion to 3.898 billion yuan, up 60% to 80% YoY.
sales prices and sales volume of key products such as vitamin E, biotin, vitamin A and methionine increased compared to the same period in 2019.
, Xin and Cheng in the interactive platform said that the company's current project planning capacity of 30,000 tons, according to the investment plan of the first phase of 5000 tons and the second phase of 10,000 tons has been officially put into production, production and sales are normal, the third phase is progressing as planned.
brokerage analysis pointed out that, on the one hand, the prices of major nutrition products increased year-on-year, driving the company's performance to grow significantly, on the other hand, the company's deep layout of Shandong base and Heilongjiang base, employee shareholdings show growth confidence.
High-rise projected net profit of 3,018 million to 3.195 billion yuan in 2020, up 70% to 80% YoY.
The main reasons are, on the one hand, the revenue growth of the holding backbone pharmaceutical enterprises, and on the other hand, the company's major asset restructuring in 2019, the company completed the acquisition of 29.5% minority shareholder in Changchun Jinsai Pharmaceutical Co., Ltd. in November 2019, so the company has consolidated the financial statements of Changchun Jinsai Pharmaceuticals at a 99.5% shareholding ratio since November 2019.
22 pharmaceutical companies lost money, 5 continued losses in the disclosed results of the pharmaceutical companies, a total of 22 expected losses, of which, Consino, Junshi Bio, Baiotai and other 5 continued losses, Shuangcheng Pharmaceuticals, Jincheng Pharmaceuticals, Zixin Pharmaceuticals and other 9 first losses.
: With the company still in the product development phase and no products on the market, the company is forecast to continue to lose money in 2020.
loss of 176 million yuan in the first three quarters of 2020, up 88.17 percent year-on-year, surpassing the full year of 2019.
, Concino landed on the board in August 2020 as a company dedicated to the development, production and sale of innovative vaccines in line with Chinese and international standards.
pipeline includes 16 innovative vaccine products for the prevention of 13 adaptations such as Ebola virus disease, meningitis, new coronavirus (COVID-19), white break, pneumonia, etc.
: Since its inception, the company has been committed to the discovery, development, production and commercialization of innovative therapies.
by 2020, through independent research and development and cooperative development, the company has a wealth of products in the pipeline, including 26 innovative drugs and 2 biosynthics, covering five therapeutic areas.
's first product, Terripley single-dose injections, has been officially commercialized since February 2019, but sales revenue for individual products is not yet covered by research and development spending in the short term and is expected to remain loss-making in 2020 as the company's business continues to expand and advance.
first three quarters of 2020, Junshi Bio's net profit loss of 1.116 billion yuan, down 150.43 percent year-on-year.
: Research and development activities in the field of biomedicine have the characteristics of high technical risk, long research and development cycle and large capital investment.
's biopharmace product pipeline is rich, research and development investment is large, currently only Adamo single anti-injection (commodity name: Gree Li) in 2020 listed for sale, the product is still in the market development stage, operating income is in a period of growth, is expected to continue to generate losses in 2020.
data show that in 2016-2019, the cumulative net profit of Baiotai was nearly 2 billion yuan, and in the first three quarters of 2020, the net profit of Baiotai was RMB106 million, up 15113 percent YoY, and the net profit loss was RMB362 million, up 59.05 percent YoY.
: Oriental Wealth Network, listed company announcements if there are omissions, welcome to point out!